Regenxbio Inc REGENXBIO RGX-314 Phase I/IIa Trial Update Transcript
Good morning, and welcome to the REGENXBIO conference call to review additional positive long-term interim Phase I/IIa trial update for RGX-314 for the treatment of wet AMD. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.
Good morning, and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and several esteemed retinal physicians and key opinion leaders: Dr. Allen Ho, Director of Retina Research at Wills Eye Hospital and Mid-Atlantic Retina; Dr. Robert Avery, Founder of California Retina Consultants and Research Foundation; and Dr. Peter Campochiaro, Director of the Retinal Cell and Molecular Laboratory at Johns Hopkins Wilmer Eye Institute.
Earlier this morning, REGENXBIO provided an update via press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
